logoAiPathly

Atropos Health

A

Overview

Atropos Health is a pioneering company in healthcare and life sciences, specializing in translating real-world clinical data into personalized real-world evidence (RWE) to improve clinical outcomes, accelerate research, and enhance operational efficiency. Key Features and Technologies:

  1. GENEVA OS™: A Generative Evidence Acceleration Operating System that securely installs on medical data, structuring it for use by clinicians, researchers, and data scientists. It enables rapid generation of high-quality, publication-grade real-world evidence.
  2. Atropos Evidence™ Network: Provides access to de-identified records of approximately 200 million global patients, allowing organizations to run queries and generate evidence quickly. It includes the Alexandria™ library, containing over 10,000 past studies across more than 40 clinical specialties.
  3. ChatRWD™ and Green Button™ Informatics Consult Service: Tools that allow users to ask clinical questions and receive evidence-based answers in minutes, facilitated by a chat-based AI co-pilot and supported by medical experts. Mission and Impact: Atropos Health aims to address the "evidence gap" in healthcare, particularly for patients with multiple comorbidities or from understudied groups. By democratizing access to high-quality RWE, the company seeks to personalize clinical decisions, optimize care protocols, and conduct population health studies more effectively. Applications and Benefits:
  4. Precision Medicine: Enhances precision medicine programs by providing personalized insights for diagnosis, treatment selection, and care management.
  5. Clinical Decision-Making: Accelerates appropriate clinical decision-making, driving high-value, low-cost care tailored to individual patient physiology.
  6. Research and Development: Expedites research by generating novel retrospective observational studies in response to clinical questions, reducing time from months to minutes.
  7. Cost Savings and Efficiency: Helps health systems reduce healthcare costs through optimized care protocols, lower research costs, and improved patient outcomes. Partnerships and Funding: Atropos Health has received significant funding, including a $33 million Series B round led by Valtruis. The company has strategic partnerships with health systems like Mayo Clinic, and life sciences companies such as Janssen and Novartis. Founding and Leadership: Founded in 2019 by Brigham Hyde, Ph.D., Nigam Shah, MBBS, Ph.D., and Saurabh Gombar, M.D., Ph.D., who are leaders in AI and real-world evidence research in healthcare. The company is headquartered in Palo Alto, CA, and has a strong advisory board of healthcare leaders.

Leadership Team

Atropos Health's leadership team comprises experienced professionals with diverse backgrounds in medicine, finance, and corporate development. Founders and Executive Leadership:

  1. Brigham Hyde, PhD: Co-Founder and Chief Executive Officer
  2. Saurabh Gombar, MD PhD: Co-Founder and Chief Medical Officer
  3. Nigam Shah, PhD MBBS: Co-Founder and Chief Data Scientist at Stanford Health Care Key Executives:
  4. Neil Sanghavi: President, Products & Solutions
  5. Sharath Reddy: Chief Financial Officer and Head of Corporate Development
  6. Vladimir Polony: Director of Engineering
  7. Yen Low, PhD: Director of Real-World Data & Data Science
  8. Cecily Harris: Legal
  9. Kris Karson: Corporate Development
  10. Rehan Chawdry: Engineering
  11. Joy Somogyi: Marketing
  12. Annie Daskovsky: Finance
  13. Kevin Smith: Health System Sales
  14. Chris Lento: Life Science Sales Advisory Boards: Atropos Health has both a Clinical Advisory Board and a Life Sciences Advisory Board, comprising healthcare industry leaders who advise on the company's strategies and innovations. Clinical Advisory Board Key Members:
  15. Nick Patel, MD: Chair of the Advisory Board
  16. Neera Ahuja, MD: Division Chief – Hospital Medicine at Stanford University School of Medicine
  17. Robert Harrington, MD: Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University
  18. Rasu Shrestha, MD, MBA: Chief Innovation and Commercialization Officer at Advocate Health Life Sciences Advisory Board Key Members:
  19. Barbara Salami: Former Vice President at Moderna
  20. Dr. Gabriel Eichler: Founder and Managing Director of Oak Health Partners This diverse leadership team brings a wealth of experience in healthcare, technology, and business, positioning Atropos Health at the forefront of AI-driven healthcare solutions.

History

Founding and Early Development:

  • Founded in 2019 as a spin-out of Stanford University's "Green Button" technology
  • Originated from a research project led by co-founders Brigham Hyde, Nigam Shah, and Saurabh Gombar
  • Aimed to leverage anonymized electronic medical records (EMRs) to inform patient care Key Milestones:
  1. Seed Funding and Initial Deployment (December 2020):
    • Announced launch and completion of seed funding round
    • Supported by Boston Millennia Founders Fund and others
    • Selected as a participant in StartX 2020
    • Deployed service within Stanford Health Care for two years
  2. Series A Funding (August 2022):
    • Raised $14 million led by Breyer Capital
    • Expanded commercial team and developed oncology product
    • Appointed Brigham Hyde as CEO
  3. Series B Funding (May 2024):
    • Secured $33 million to scale AI-powered real-world evidence platform
    • Focused on life sciences partnerships and international expansion Technological Advancements:
  4. Geneva OS (Fall 2023):
    • Includes ChatRWD chatbot interface
    • Reduces time to produce high-quality real-world evidence
  5. Atropos Evidence Platform:
    • Uses search technology licensed from Stanford University
    • Generated over 50 peer-reviewed studies
  6. Atropos Evidence Network:
    • Federal data network based on healthcare institution partners
    • Access to over 200 million unique de-identified patient records Significant Partnerships:
  • Janssen Research & Development
  • Cencora
  • Arcadia
  • xCures
  • Strategic funding from Presidio Ventures, Samsung Next, Gaingels, and Audere Capital Mission and Impact:
  • Aims to fill the evidence gap in healthcare
  • Provides personalized real-world data-driven evidence to caregivers
  • Improves patient outcomes and reduces healthcare expenditures
  • Saved clients over $100 million through expedited analytics and cost-saving measures Atropos Health's history reflects rapid growth and innovation in the field of AI-driven healthcare solutions, positioning the company as a leader in real-world evidence generation and application.

Products & Solutions

Atropos Health offers innovative solutions leveraging real-world data (RWD) to support clinical decision-making, research, and operational efficiency in healthcare and life sciences:

  1. Evidence Generation Solutions: Translates real-world clinical data into personalized real-world evidence (RWE) to close evidence gaps.
  2. GENEVA OS™: The Generative Evidence Acceleration Operating System securely installs on medical data, structuring it for use by clinicians, researchers, and data scientists. Users can ask clinical questions via ChatRWD™ or the Green Button™ Informatics Consult Service.
  3. Atropos Evidence™ Network and Alexandria™: Provides access to de-identified records of approximately 200 million global patients and a library of over 10,000 past studies across 40+ clinical specialties.
  4. Advanced Cohort Engine (ACE): Developed in collaboration with Stanford clinicians, ACE searches longitudinal patient records using Temporal Query Language (TQL).
  5. Real-Time Analytics and Comparative Effectiveness Research: Enables organizations to monitor interventions in real-time and optimize clinical operations, care pathways, and drug formularies.
  6. Clinical Decision Support: Accelerates appropriate clinical decision-making, supported by medical doctors, epidemiologists, statisticians, and other experts.
  7. Integration and Security: HIPAA-compliant and integrates with various health systems, allowing quick deployment and immediate access to the Atropos Evidence™ Network.
  8. Pricing and Accessibility: Available on platforms like AWS Marketplace, with pricing starting from $1.00/hr or $100.00/yr, plus AWS usage fees. Atropos Health's solutions aim to transform healthcare by providing rapid, methodologically credible real-world evidence, supporting better clinical decisions, research, and operational efficiency.

Core Technology

Atropos Health's core technology revolves around several key components that facilitate the use of real-world data (RWD) and artificial intelligence (AI) in healthcare:

  1. GENEVA OS™: The Generative Evidence Acceleration Operating System is designed for rapid healthcare evidence generation across a robust network of real-world data. It automates and standardizes evidence and insight generation for healthcare and life science institutions.
  2. Atropos Evidence™ Network: A federated healthcare data network providing access to over 300 million patient records. This network enables training, testing, and deployment of AI models using high-quality, de-identified real-world data, benefiting AI developers, health systems, life sciences organizations, and data holders.
  3. ChatRWD™: An AI co-pilot integrated with GENEVA OS™, using an LLM-independent framework to maintain security and integrity. It significantly reduces the time required to produce high-quality, publication-grade real-world evidence from months to minutes.
  4. Real-World Data (RWD) and Real-World Evidence (RWE): The platform leverages RWD to generate RWE, crucial for improving patient care and outcomes. This approach ensures AI models output accurate recommendations for researchers and clinicians, supporting precision medicine initiatives.
  5. Automation and Transparency: Built on principles of quality, transparency, and automation, Atropos Health prioritizes patient safety and responsible AI use. The technology ensures AI models are developed and deployed with emerging assurance standards on AI transparency and bias detection. Atropos Health's core technology combines these elements to provide a comprehensive platform for generating and utilizing real-world evidence in healthcare, supporting rapid clinical decision-making, research, and operational efficiency.

Industry Peers

Atropos Health operates within the digital health and healthcare analytics sector. Here are some of its key industry peers and competitors:

  1. Komodo Health: Specializes in healthcare analytics, providing insights from a range of healthcare data to improve patient care and reduce disease burden.
  2. Holmusk: Focuses on behavioral health, offering a real-world evidence platform leveraging AI-powered analytics and digital solutions.
  3. Evidation: Harnesses real-world health data to measure and improve health outcomes, serving life sciences companies, government bodies, and academic institutions.
  4. Tempus: Known for advanced genomic and transcriptomic analysis, providing personalized cancer treatment options and real-world evidence generation.
  5. Paradigm: While not exclusively focused on healthcare analytics, it competes with Atropos Health in terms of overall market presence and revenue scale.
  6. Datavant: Specializes in linking health data to improve patient outcomes, often mentioned alongside Atropos Health in industry analyses. Key Differentiators: Atropos Health stands out with its Evidence Network, allowing users to query a vast network of patient data (over 300 million patients) without data sales, ensuring HIPAA compliance and data security. It utilizes generative AI to produce real-world evidence reports quickly and at scale. Similarities: These companies share a focus on leveraging large datasets and advanced analytics to improve healthcare outcomes, optimize health systems, and accelerate clinical research. However, each has a unique approach and area of specialization within the broader healthcare technology landscape. Atropos Health's combination of a vast patient data network, generative AI capabilities, and focus on rapid, scalable evidence generation positions it uniquely in the competitive landscape of healthcare analytics and real-world evidence platforms.

More Companies

e

eFishery

eFishery is an innovative aquaculture technology startup founded in 2013, headquartered in Indonesia. Recognized as the first Aquaculture Technology startup in Asia, eFishery has revolutionized the industry with its data-driven solutions. ### Mission and Objectives eFishery's core mission is to transform the aquaculture industry by providing cutting-edge, data-driven solutions. The company aims to empower fish and shrimp farmers with smart feeding technology and data analytics, helping them increase efficiency, reduce waste, and boost profits. This aligns with their broader goal of combating world hunger by harnessing the potential of aquaculture. ### Technology and Solutions eFishery has developed several key technologies: 1. IoT-based Smart Feeding Machine: Uses sensors to determine fish hunger and dispense optimal feed amounts, reducing feeding costs which typically account for 60-90% of total production costs. 2. Cloud-Based Dashboard and Data Platform: Allows farmers to manage feeding in real-time via smartphones and control the system remotely. The collected data is aggregated, stored, and analyzed in the cloud. 3. End-to-End Platform: Offers access to feed, financing, and market opportunities for fish and shrimp farmers, creating a comprehensive aquaculture ecosystem. ### Impact eFishery has made significant strides in the aquaculture industry: - User Base: Worked with over 23,000 fish and shrimp ponds across Indonesia, with more than 13,000 farmers as paid users. - Profit Increase: Farmers using eFishery's solutions have seen an average profit increase of over 20%. - Market Position: Currently the largest feed distributor and fish supplier in Indonesia, despite not operating any ponds directly. ### Core Values eFishery is guided by several core values: - Sustainability: Promoting sustainable aquaculture practices - Innovation: Encouraging creativity and new solutions - Collaboration: Fostering a diverse and collaborative environment - Customer Focus: Commitment to exceptional service - Continuous Improvement: Constantly enhancing products and services ### Recent Developments eFishery has recently raised $415 million in funding, although it has faced challenges, including the suspension of its co-founders amid a financial investigation. The company has launched a sustainability and impact report, highlighting its commitment to responsible aquaculture practices. Additionally, eFishery has partnered with other companies to enhance financial inclusion and literacy among fish farmers.

P

Planet

Our solar system comprises eight major planets, as defined by the International Astronomical Union (IAU). These planets, in order from closest to farthest from the Sun, are: - Mercury - Venus - Earth - Mars - Jupiter - Saturn - Uranus - Neptune The planets can be categorized into several groups based on their composition and characteristics: ### Terrestrial Planets Mercury, Venus, Earth, and Mars are small, rocky planets with relatively thin atmospheres, primarily composed of rock and metal. ### Giant Planets #### Gas Giants Jupiter and Saturn are the largest planets, primarily composed of hydrogen and helium gases with dense atmospheres. #### Ice Giants Uranus and Neptune are composed mainly of low-boiling-point materials such as water, methane, and ammonia, with thick atmospheres of hydrogen and helium. All planets orbit the Sun in the same direction and approximately in the same plane, following nearly circular orbits. Their sizes and masses vary significantly, with Jupiter being the largest (diameter: 139,822 km) and Mercury the smallest (diameter: 4,879 km). In addition to the major planets, the solar system includes dwarf planets (e.g., Pluto, Eris), moons, asteroids, comets, and meteoroids. The prevailing theory of planet formation is the nebular hypothesis, suggesting that planets form from the collapse of an interstellar cloud into a protostar surrounded by a protoplanetary disk. Each planet has unique features: - Venus: Hottest planet due to its thick atmosphere causing a greenhouse effect - Earth: Only known habitable planet with diverse surface and moderate atmosphere - Mars: Home to the largest volcano in the solar system, Olympus Mons - Jupiter: Strong magnetic field and more than double the mass of all other planets combined - Saturn: Most moons among the planets - Uranus and Neptune: Ice giants with thick atmospheres and unique compositions

A

Africa Finance Corporation

The Africa Finance Corporation (AFC) is a multilateral financial institution established in 2007 to address Africa's infrastructure deficits and promote economic growth. Here are the key aspects of the AFC: ### Establishment and Ownership AFC was founded with an anchor investment from the Central Bank of Nigeria (CBN) and 17 private institutional investors. Today, it has 31 shareholders, including 10 sovereign states, 3 multilateral organizations, and 18 private institutional investors. The CBN remains the largest shareholder, holding approximately 41.89% of AFC's shares. ### Mission and Business Model AFC's mission is to foster economic growth and industrial development in African countries while delivering competitive returns to shareholders. It operates through a unique value proposition, offering services in project development, financial advisory, and principal investing. AFC participates across the entire project cycle and capital structure, ensuring well-structured projects and successful financial closures. ### Investment and Funding Since its inception, AFC has mobilized up to $5.1 billion from global debt markets and deployed over $12.7 billion in investments across 36 African countries. The corporation employs a diverse funding strategy, including tapping into niche markets, diversifying funding sources, and leveraging market opportunities. AFC has issued various financial instruments such as Eurobonds, green bonds, and syndicated loans to enhance its investment capacity. ### Focus Areas and Projects AFC focuses on financing infrastructure, natural resources, and industrial assets to enhance productivity and economic growth in African states. Its projects span several sectors, including: - Power - Agriculture - Regional integration - Rural value chains - Manufacturing - Trade-related infrastructure The corporation also invests in climate change adaptation and mitigation projects, such as renewable energy generation and sustainable transport. ### Strategic Partnerships and Accreditations AFC has established strategic partnerships with other regional financial institutions and has been accredited by the Green Climate Fund (GCF) since 2015. This accreditation enables AFC to implement projects that address Africa's infrastructural gaps while promoting low-emission and climate-resilient development pathways. ### Development Outcomes AFC's investments aim to address the critical infrastructure gap in Africa, promote industries, create jobs, add value, and stimulate overall economic growth. The corporation also supports intra-African trade and regional integration, facilitating the importation of critical capital goods, agricultural inputs, medical supplies, and foodstuffs. In summary, the Africa Finance Corporation plays a pivotal role in addressing Africa's infrastructure challenges through a comprehensive approach that includes project development, financial advisory, and principal investing, while fostering economic growth and industrial development across the continent.

A

Agility Robotics

Agility Robotics, Inc. is a pioneering American company in the field of humanoid robotics and engineering. Founded in 2015 as a spin-off from Oregon State University's Dynamic Robotics Lab, the company has quickly established itself as a leader in industrial humanoid robot development. Key Highlights: - Founding: Co-founded by Jonathan Hurst, Damion Shelton, and Mikhail Jones, building on Hurst's research in dynamic stability and bipedal locomotion. - Products: 1. Cassie (2016): A bipedal robot without an upper body, sold as a research platform. 2. Digit (2017): A full-size humanoid robot with a torso, arms, and advanced perception systems. - Technology: Digit features a unique bipedal structure, advanced AI capabilities, and operates on a Linux-based real-time system powered by Intel i7 processors. - Partnerships: Collaborations with companies like GXO Logistics and Amazon for logistics and warehouse applications. - Funding: Raised $179.6 million to date, including a $150 million round in 2024. - Manufacturing: Established RoboFab, a humanoid robotics factory in Salem, Oregon. Agility Robotics focuses on developing autonomous robots for supply chain, manufacturing, and logistics sectors. Their flagship product, Digit, is designed for tasks such as lifting, carrying, and placing items in various industrial settings. The company continues to innovate in areas such as safety features, battery efficiency, and advanced AI integration, positioning itself at the forefront of the industrial humanoid robot market.